Li Fangjie, Qian Weixiang, Wang Jiayao, Gao Minghua
Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Huzhou Normal University, Huzhou, China.
J Craniofac Surg. 2025 Jun 1;36(4):1401-1407. doi: 10.1097/SCS.0000000000010906. Epub 2024 Nov 25.
Previous studies have shown that follistatin-like protein 1 (FSTL1) is elevated in the synovial fluid of osteoarthritis and whether it is associated with disease development progress in cartilage degeneration is still unclear. The experiment was performed to explore the effect and mechanism of FSTL1 on chondrocyte degeneration and its further impaction in osteoarthritis as well as its treatment method.
The patients who were diagnosed with temporomandibular joint (TMJ) disc displacement and osteoarthritis (OA) group was divided into 2 groups, anterior disc displacement (ADD) without bone resorption and ADD with bone resorption group according to the radiologic examination. The ELISA kit was used to determine the expression level of FSTL1 in patients TMJ environment. The function of FSTL1 in promoting chondrocyte degeneration was tested by quantitative reverse transcription polymerase chain reaction (Rt-qPCR) and western blot. The chondrocyte apoptosis and mitophagy were further test by flow cytometry and mitosox staining by upregulating and downregulating of FSTL1. In the end, the effectiveness of regulating FSTL1 in OA procedure was further validated by hematoxylin-eosin (HE), safranin O, and immunohistochemical (IHC) staining in vivo.
There were 56 samples collected from the patients were included into this study. According to the ELISA results, FSTL1 expression levels of ADD without bone resorption groups were significantly lower than that in ADD with bone resorption group. Furthermore, the rate of cell apoptosis cells and the mitophagy procedure were highly activated when FSTL1 was upregulated. The morphology analysis of mitochondria showed significant changes when FSTL1 was highly upregulated in vitro. The in vivo and in vitro experiments showed that suppressing FSTL1 could alleviate the cartilage degeneration in TMJ OA progression.
To sum up, upregulated expression level of FSTL1 in synovial fluid promoted the progression of TMJ OA by upregulating accelerating the chondrocyte apoptosis and mitophagy, and suppressing the FSTL1 in TMJ can rescue the OA progression. Therefore, it may be a promising result to consider the FSTL1 as a therapeutic target in the future.
先前的研究表明,卵泡抑素样蛋白1(FSTL1)在骨关节炎滑液中升高,其是否与软骨退变中的疾病发展进程相关仍不清楚。进行该实验以探究FSTL1对软骨细胞退变的作用及机制、其在骨关节炎中的进一步影响以及治疗方法。
将诊断为颞下颌关节(TMJ)盘移位和骨关节炎(OA)的患者根据影像学检查分为2组,即无骨质吸收的前盘移位(ADD)组和有骨质吸收的ADD组。使用酶联免疫吸附测定(ELISA)试剂盒测定患者TMJ环境中FSTL1的表达水平。通过定量逆转录聚合酶链反应(Rt-qPCR)和蛋白质印迹法检测FSTL1促进软骨细胞退变的功能。通过上调和下调FSTL1,进一步用流式细胞术检测软骨细胞凋亡和线粒体自噬,并进行Mitosox染色。最后,通过苏木精-伊红(HE)染色、番红O染色和免疫组织化学(IHC)染色在体内进一步验证调节FSTL1在OA病程中的有效性。
本研究共纳入56例患者的样本。根据ELISA结果,无骨质吸收的ADD组FSTL1表达水平显著低于有骨质吸收的ADD组。此外,上调FSTL1时细胞凋亡率和线粒体自噬过程高度激活。体外FSTL1高度上调时线粒体形态分析显示出显著变化。体内和体外实验均表明,抑制FSTL1可减轻TMJ OA进展中的软骨退变。
综上所述,滑液中FSTL1表达水平上调通过加速软骨细胞凋亡和线粒体自噬促进TMJ OA进展,抑制TMJ中的FSTL1可挽救OA进展。因此,将来将FSTL1作为治疗靶点可能会取得有前景的结果。